Related references
Note: Only part of the references are listed.Haem is crucial for medium-dependent metronidazole resistance in clinical isolates of Clostridioides difficile
Ilse M. Boekhoud et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Global Landscape of Clostridioides Difficile Phylogeography, Antibiotic Susceptibility, and Toxin Polymorphisms by Post-Hoc Whole-Genome Sequencing from the MODIFY I/II Studies
Hailong Zhao et al.
INFECTIOUS DISEASES AND THERAPY (2021)
The Integrity of Heme Is Essential for Reproducible Detection o Metronidazole-Resistant Clostridioides difficile by Agar Dilution Susceptibility Tests
Xiaoqian Wu et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2021)
Plasmid-mediated metronidazole resistance in Clostridioides difficile
Ilse M. Boekhoud et al.
NATURE COMMUNICATIONS (2020)
Chromosomal Resistance to Metronidazole in Clostridioides difficile Can Be Mediated by Epistasis between Iron Homeostasis and Oxidoreductases
Aditi Deshpande et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Trends in US Burden of Clostridioides difficile Infection and Outcomes
Alice Y. Guh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
US-Based National Surveillance for Fidaxomicin Susceptibility of Clostridioides difficile-Associated Diarrheal Isolates from 2013 to 2016
C. M. Thorpe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms
Simon A. Dingsdag et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)
L. Clifford McDonald et al.
CLINICAL INFECTIOUS DISEASES (2018)
PCR ribotyping and antimicrobial susceptibility testing of isolates of Clostridium difficile cultured from toxin-positive diarrheal stools of patients receiving medical care in Canadian hospitals: the Canadian Clostridium difficile Surveillance Study (CAN-DIFF) 2013-2015
James A. Karlowsky et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2018)
US- Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin
D. R. Snydman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
A national survey of the molecular epidemiology of Clostridium difficile in Israel: the dissemination of the ribotype 027 strain with reduced susceptibility to vancomycin and metronidazole
Amos Adler et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Burden of Clostridium difficile Infection in the United States
Fernanda C. Lessa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Investigation of potentially pathogenic Clostridium difficile contamination in household environs
M. Jahangir Alam et al.
ANAEROBE (2014)
Vancomycin, Metronidazole, or Tolevamer for Clostridium difficile Infection: Results From Two Multinational, Randomized, Controlled Trials
Stuart Johnson et al.
CLINICAL INFECTIOUS DISEASES (2014)
The pyrazinamide susceptibility breakpoint above which combination therapy fails
Tawanda Gumbo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections
Christina M. Surawicz et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Analysis of metronidazole susceptibility in different Clostridium difficile PCR ribotypes
Ines Moura et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
The Roles of Clostridium difficile and Norovirus Among Gastroenteritis-Associated Deaths in the United States, 1999-2007
Aron J. Hall et al.
CLINICAL INFECTIOUS DISEASES (2012)
Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance
Dhara Shah et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2010)
Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
Stuart H. Cohen et al.
INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2010)
Comparison of clinical and microbiological response to treatment of Clostridium difficile associated disease with metronidazole and vancomycin
Wafa N. Al-Nassir et al.
CLINICAL INFECTIOUS DISEASES (2008)
Emergence of reduced susceptibility to metronidazole in Clostridium difficile
Simon D. Baines et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Characterization of Clostridium difficile strains isolated from patients in Ontario, Canada, from 2004 to 2006
H. Martin et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Metronidazole resistance in Clostridium difficile is heterogeneous
T. Pelaez et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2008)
Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007
A. Indra et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2008)
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile -: Associated diarrhea, stratified by disease severity
Fred A. Zar et al.
CLINICAL INFECTIOUS DISEASES (2007)
In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004
David W. Hecht et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish University Hospital
O Aspevall et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada
J Pépin et al.
CLINICAL INFECTIOUS DISEASES (2005)
Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole
DM Musher et al.
CLINICAL INFECTIOUS DISEASES (2005)
Comparison of the E test to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile
I Poilane et al.
CLINICAL MICROBIOLOGY AND INFECTION (2000)
Share Paper
